You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Mayo Clinic researchers found that cytogenetic subtypes containing three translocations were more common in individuals with a greater proportion of African ancestry.
In granting de novo premarket authorization to ClonoSeq, the agency established its regulatory expectations for similar tests.
These and previously uncovered multiple myeloma risk loci may influence disease by affecting developmental transcriptional regulators.
The platform integrates whole exome and RNA sequencing for downstream RNA-based drug repurposing to treat patients with relapsed multiple myeloma.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.
The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.
Evidence is accumulating that analyzing cell-free DNA and/or samples from circulating tumor cells provides a good surrogate for bone marrow in these patients.
The researchers found that both coding and non-coding alterations drive the early development of multiple myeloma.
The test measures the multiple myeloma marker M protein and could prove more sensitive and less susceptible to interferences than existing assays.
Researchers found rare mutations in USP45 and ARID1A by applying a shared genomic segment mapping approach to several large multiple myeloma-affected families.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.
A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.